Literature DB >> 17112204

Moyamoya disease in the midwestern United States.

N M Wetjen1, P C Garell, N V Stence, C M Loftus.   

Abstract

There have been few investigations of moyamoya disease in the United States and no systematic description of the management practices or outcome from this population. The authors reviewed their experience with this disease to gain a better understanding and improve the treatment of patients with moyamoya disease in the United States. Over a 25-year period 30 patients with moyamoya disease have been treated at the University of Iowa. The cases were divided into patients who had classic, probable, and akin moyamoya disease. Results indicated that there was a bimodal age distribution and a female predominance of cases. In estimating the referral pattern of our institution, the authors determined that there were greater numbers of epidemiological characteristics than previously anticipated. Patients were treated either surgically or nonsurgically, and different management strategies were utilized in each of the major groups: superficial temporal artery to middle cerebral artery anastomosis and encephalodurosynangiosis in the surgical group; or antiplatelet, anticoagulation, or nonpharmacological intervention in the nonsurgical group. The authors conclude that there is a higher prevalence and incidence of moyamoya disease in the United States than previously reported and that there are some clinical characteristics of this disease that differ from the cases reported in southeast Asia. These differences may be due to genetic or environmental factors but can also be partly explained by the lower index of suspicion for this disease and, thus, a delay in or complete absence of the correct diagnosis.

Entities:  

Year:  1998        PMID: 17112204     DOI: 10.3171/foc.1998.5.5.4

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  8 in total

1.  Cerebrovascular collaterals correlate with disease severity in adult North American patients with Moyamoya disease.

Authors:  M K Strother; M D Anderson; R J Singer; L Du; R D Moore; Y Shyr; T R Ladner; D Arteaga; M A Day; P F Clemmons; M J Donahue
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-20       Impact factor: 3.825

2.  Missing relationship of moyamoya and persistent primitive artery in Europeans. Another distinctive feature or artifact?

Authors:  Holger Wenz; Ralf Wenz; Alex Förster; Johann Fontana; Hans Ulrich Kerl; Christoph Groden; Johann Scharf
Journal:  Surg Radiol Anat       Date:  2015-03-08       Impact factor: 1.246

Review 3.  Moyamoya disease: a clinical spectrum, literature review and case series from a tertiary care hospital in Pakistan.

Authors:  Sana Shoukat; Ahmed Itrat; Ather M Taqui; Moazzam Zaidi; Ayeesha K Kamal
Journal:  BMC Neurol       Date:  2009-04-15       Impact factor: 2.474

4.  Moyamoya disease presented as a case of hemiplegic migraine.

Authors:  M R Siddiqui; S U Khan; M A Hoque; K M Rahman; M B A Mondol; Q D Mohammad
Journal:  BMJ Case Rep       Date:  2010-11-12

5.  Epidemiology of Moyamoya Disease in Korea: Based on National Health Insurance Service Data.

Authors:  Tackeun Kim; Heeyoung Lee; Jae Seung Bang; O-Ki Kwon; Gyojun Hwang; Chang Wan Oh
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

6.  Rarer in a rare.

Authors:  B Taksande; Mm Patil; P Banode; R Deshpande
Journal:  Ann Med Health Sci Res       Date:  2013-01

Review 7.  The Genetic Basis of Moyamoya Disease.

Authors:  R Mertens; M Graupera; H Gerhardt; A Bersano; E Tournier-Lasserve; M A Mensah; S Mundlos; P Vajkoczy
Journal:  Transl Stroke Res       Date:  2021-09-16       Impact factor: 6.829

Review 8.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.